Lachen, Switzerland--(BUSINESS WIRE)--Octapharma today announced that it will hold a satellite seminar and poster presentation at the 14th annual meeting of the European Society for Hemophilia and Related Disorders (EAHAD), which will be held in 2021 It will be held on a virtual basis from February 3 to 5
The "Nuwiq ® Family Journey: Early Treatment Decisions for Long-term Health" satellite seminar will be hosted by Dr. Robert F. Sidonio Jr. (Haemophilia Department, Georgia Bleeding and Coagulation Disorders Center, Atlanta, USA, Emory University Atlanta Children's Healthcare Center) , The seminar will track the treatment history of a family with two sons diagnosed with severe hemophilia A. The speaker will discuss key treatment decisions and considerations for long-term health under the evolving hemophilia A treatment landscape, including prevention and treatment of bleeding, inhibitor risk, inhibitor elimination, and bone and joint health. The seminar will be held on the EAHAD online platform at 18:00 on February 4, 2021, Central European Time.
In the poster session, Dr. Sylvia Horneff (Institute of Experimental Hematology and Transfusion Medicine, Bonn University Hospital, Germany) will present a single-center experience of 46 patients with acquired hemophilia A (a rare autoimmune disease) bleeding treatment. Including 9 patients treated with octanate®:
Poster ABS193 high doses of plasma-derived FVIII acquired hemophilia A safety and efficacy (Di Prinzio G, etc.)
Larisa Belyanskaya, Head of Hematology at Octapharma IBU, commented: “ We are honored to share the real experience of Nuwiq® positively affecting children with hemophilia A. Combined with the clinical trial data of our full lineup of products, such experience can provide a reference for treatment decisions. With the continuous emergence of new therapies, treatment decisions are becoming increasingly complex. "
Olaf Walter, Octapharma's board member, added: " Octapharma 's ultimate goal is to improve the lives of patients. We are sincerely proud to see that our work is helping to achieve this goal. Our contribution to the EAHAD conference demonstrates our commitment, namely Allow hemophilia A patients to enjoy a long, active and healthy life. "
About Octapharma
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, dedicated to the development and production of human proteins derived from human plasma and human cell lines. Octapharma employs more than 10,000 employees worldwide and supports the treatment of patients in 118 countries with products in the following three areas: hematology, immunotherapy and intensive care.
Octapharma has seven R&D facilities and six first-class manufacturing facilities in Austria, France, Germany, Mexico and Sweden, with a total annual plasma preparation output of approximately 8 million liters. In addition, Octapharma operates more than 140 plasma donation centers in Europe and the United States.
About Nuwiq®
Nuwiq® (simoctocog alfa) is a fourth-generation recombinant factor VIII (rFVIII) protein, produced in human cell lines without chemical modification or any other protein fusion1. The culture does not contain human or animal-derived additives, does not contain non-human protein epitopes, and has a high affinity for von Willebrand factor1. Seven clinical trials evaluating Nuwiq® treatment have been completed, involving 201 treated patients with severe hemophilia A (PTP; 190), including 59 children1. Nuwiq® is available in 250 IU, 500 IU, 1000 IU, 2000 IU, 2500 IU, 3000 IU and 4000 IU equal-dose packages2. Nuwiq® is approved for the treatment and prevention of bleeding in patients with hemophilia A (congenital FVIII deficiency) in all age groups2.
1. Lissitchkov T et al. Ther Adv Hematol 2019; doi: 10.1177/2040620719858471.
2. Nuwiq® Summary of Product Characteristics. (Nuwiq® Product Characteristics Overview)
About octanate®
Octanate® is a human plasma-derived, high-purity, freeze-dried, double virus-inactivated factor VIII (FVIII) concentrate for intravenous administration1,2. The coagulated FVIII contained in octanate® combines with its natural stabilizing factor von Willebrand factor (VWF) at a VWF/FVIII ratio of about 0.41. Therefore, there is no need to add a stabilizing factor during the manufacturing process. octanate® is available in 3 dosage packages: 250 IU, 500 IU and 1000 IU 1. Octanate® was first approved more than 20 years ago and has been approved in more than 85 countries for the prevention and treatment of bleeding in patients with hemophilia A (congenital FVIII deficiency) in all age groups1. This dosage package is not suitable for von Willebrand disease. octanate® is also approved for immune tolerance induction (ITI) in more than 40 countries.
- Klukowska A et al. Haemophilia 2018; 24:221-8.
- octanate® Summary of Product Characteristics. (octanate® product characteristics overview)